It is a group made up of cardiologists (Antonio Fernández-Ortiz, Iván Núñez-Gil, David Vivas, Ana Viana, Javier Nogueira, and Javier Higueras) and biologists (Esther Bernardo). The healthcare work is integrated into the coronary unit, the hospitalisation ward, and haemodynamic wards, and the common research facilities of the Cardiovascular Institute are available. In recent years, the group has focused on the study of platelet reactivity/leukocyte activation in patients treated with coronary angioplasty, in patients with acute myocardial syndromes, and in diabetics. Clinical aspects of transient apical dyskinesia syndromes have also been studied. We have recently opened a line on mechanisms involved in ischaemia/reperfusion injury and the role of a new form of beta-blocker administration in the prevention of ischaemia/reperfusion injury in patients with acute myocardial infarction. We also assessed the role of circadian rhythm in ischaemia/reperfusion tolerance. The group’s most outstanding publications in the last 5 years include 3 articles in the Journal of American College of Cardiology, 2 in Diabetes, 2 in Heart, 3 in the American Journal of Cardiology, and 5 in Revista Española de Cardiología. The group actively participates in numerous multicentre clinical trials and receives competitive funding from official calls (HORIZON 2020, ISCIII, FICI, CNIC, SEC MM). In collaboration with the CNIC, pre-clinical studies related to cardioprotection during myocardial infarction are being developed, the results of which will be tested as “proof-of-concept” in phase I and II studies in the coronary unit.
Antonio Fernandez Ortiz works as a cardiologisti in the Hospital Clínico San Carlos de Madrid since 1994. Since 2008 he has been Head of Section, responsible for the Coronary Unit, and the Haemodynamics and Interventional Cardiology Unit. Dr. Fernandez Ortiz received a Licentiate degree in Medicine from the Universidad Autónoma de Madrid in 1985 and obtained his PhD degree from the Complutense University of Madrid in 1992. He was a resident medical intern (MIR) at the Hospital Clínico San Carlos in 1986-1991, and later received a fellowship for further studies from the Fondo de Investigaciones Sanitarias of the Instituto Carlos III for two years at the Vascular Biology Laboratory of the Massachusetts General Hospital of Harvard University in Boston (USA). In 2001-2004 he was Honorary Collaborator in the Department of Medicine of the Complutense University, and since 2005 he is Associate Professor in this Department. He is a member of the Spanish Society of Cardiology, Fellow of the European Society of Cardiology, European Acute Cardiac Care Association, and the Thrombosis Group of the European Society of Cardiology. From 2009 to 2013 he has been Secretary, and then, President of the Section of Ischaemic Heart Disease and Coronary Units of the Spanish Society of Cardiology. He has authored or co-authored 393 original published articles in scientific journals, 23 chapters in textbooks, and more than 400 national and international papers, and conferences. The overall impact factor of Dr. Fernandez Ortiz is 657.414 and the H index is 36. His unit collaborates in numerous trials, co-authoring and coordinating some of them (NEJM 2015, 2017, JACC 2014, 2016, CIRCULATION 2014, EHJ 2014), and he is a leader in interventional and coronary physiology studies (EHJ 2018, NEJM 2017, JACC 2016, CIRCULATION 2015, 2016, CIR RES 2014). At CNIC, Dr. Fernandez Ortiz is scientific coordinator of the PESA study (Progression and Early Detection of Subclinical Atherosclerosis, PI: Dr. Fuster) with high impact published results (CIRCULATION 2015, JACC 2016, 2017, 2019, 2020, 2021, DIABETES 2016), and he is national coordinator of the SECURE Project (Secondary Prevention of Cardiovascular Disease in the Elderly, PI: Dr. Fuster) financed with €6M of European H2020 funds. Dr. Fernández-Ortiz has received numerous public and private research grants. Fernández-Ortiz has received numerous public and private research grants (FIS, SEC, MM, CNIC. He is a member of the Spanish Society (SEC) and the European Society of Cardiology (ESC), he has been president of the Ischaemic Heart Disease Group of the SEC (2012-14), member of the board of trustees of the Interhospital Foundation for Cardiovascular Research (FIC) and president of the same since 2017, member of the external advisory committee of the Instituto Murciano de Investigación Biosanitaria (IMIB) since 2015, member of the editorial committee of the Revista Española de Cardiología (1996-2015), and of the committee of CardioRed 1. In 2022, he has been appointed Director Cardiovascular Institute of the Hospital Clínico San Carlos.